Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jan Hillson, MD
ZymoGenetics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
79 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Herston, Queensland, Australia
- Facility name not stated
Adelaide, Australia
- Facility name not stated
Camperdown, Australia
- Facility name not stated
Clayton, Australia
- Facility name not stated
Fitzroy, Australia
- Facility name not stated
Fremantle, Australia
- Facility name not stated
Greenslopes, Australia
- Facility name not stated
Herston, Australia
- Facility name not stated
Kogarah, Australia
- Facility name not stated
Melbourne, Australia
- Facility name not stated
Penrith, Australia
- Facility name not stated
Perth, Australia
- Facility name not stated
Westmead, Australia
- Facility name not stated
Graz, Austria
- Facility name not stated
Innsbruck, Austria
- Facility name not stated
Linz, Austria
- Facility name not stated
Vienna, Austria
- Facility name not stated
Vancouver, British Columbia, Canada
- Facility name not stated
London, Ontario, Canada
- Facility name not stated
Toronto, Ontario, Canada
- Facility name not stated
Paris, France
- Facility name not stated
Pessac, France
- Facility name not stated
Bochum, Germany
- Facility name not stated
Cologne, Germany
- Facility name not stated
Düsseldorf, Germany
- Facility name not stated
Essen, Germany
- Facility name not stated
Frankfurt am Main, Germany
- Facility name not stated
Freiburg im Breisgau, Germany
- Facility name not stated
Göttingen, Germany
- Facility name not stated
Hamburg, Germany
- Facility name not stated
Hanover, Germany
- Facility name not stated
Heidelberg, Germany
- Facility name not stated
Mainz, Germany
- Facility name not stated
München, Germany
- Facility name not stated
Tübingen, Germany
- Facility name not stated
Milan, Italy
- Facility name not stated
Bialystok, Poland
- Facility name not stated
Krakow, Poland
- Facility name not stated
Racibórz, Poland
- Facility name not stated
Wroclaw, Poland
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2010
- Primary completion
- 30 Nov 2010
- Completion
- 31 May 2012
- Last update posted
- 5 Dec 2011
- Registered enrollment
- 600
- Registry id
- NCT01001754
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.